vs
AVANOS MEDICAL, INC.（AVNS）与Anteris Technologies Global Corp.（AVR）财务数据对比。点击上方公司名可切换其他公司
AVANOS MEDICAL, INC.的季度营收约是Anteris Technologies Global Corp.的583.5倍（$180.9M vs $310.0K）。AVANOS MEDICAL, INC.净利率更高（-0.7% vs -9420.0%，领先9419.3%）。AVANOS MEDICAL, INC.自由现金流更多（$21.3M vs $-18.9M）
Avanos Medical是一家医疗科技企业，专注于研发生产临床医疗设备，核心业务围绕疼痛管理与慢性护理两大板块展开，致力于帮助患者加快康复、预防感染，同时减少临床治疗中阿片类药物的使用。
Anteris Technologies Global Corp是一家专注于结构性心脏病诊疗解决方案的医疗科技企业，开发及商业化生物假体心脏瓣膜、经导管介入产品，服务北美、欧洲及亚太地区的医疗机构，核心业务覆盖心脏外科与介入心脏病学领域。
AVNS vs AVR — 直观对比
营收规模更大
AVNS
是对方的583.5倍
$310.0K
净利率更高
AVNS
高出9419.3%
-9420.0%
自由现金流更多
AVNS
多$40.2M
$-18.9M
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $180.9M | $310.0K |
| 净利润 | $-1.3M | $-29.2M |
| 毛利率 | 47.5% | 70.6% |
| 营业利润率 | 1.4% | -9343.5% |
| 净利率 | -0.7% | -9420.0% |
| 营收同比 | 0.7% | — |
| 净利润同比 | 99.7% | — |
| 每股收益（稀释后） | $-0.02 | $-0.74 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVNSAVR
| Q4 25 | $180.9M | $310.0K | ||
| Q3 25 | $177.8M | $429.0K | ||
| Q2 25 | $175.0M | $618.0K | ||
| Q1 25 | $167.5M | $556.0K | ||
| Q4 24 | $179.6M | — | ||
| Q3 24 | $170.4M | — | ||
| Q2 24 | $171.7M | — | ||
| Q1 24 | $166.1M | — |
净利润AVNSAVR
| Q4 25 | $-1.3M | $-29.2M | ||
| Q3 25 | $-1.4M | $-22.2M | ||
| Q2 25 | $-76.8M | $-20.8M | ||
| Q1 25 | $6.6M | $-21.9M | ||
| Q4 24 | $-397.3M | — | ||
| Q3 24 | $4.3M | — | ||
| Q2 24 | $1.8M | — | ||
| Q1 24 | $-900.0K | — |
毛利率AVNSAVR
| Q4 25 | 47.5% | 70.6% | ||
| Q3 25 | 48.4% | 71.3% | ||
| Q2 25 | 52.6% | 76.1% | ||
| Q1 25 | 53.6% | 62.8% | ||
| Q4 24 | 54.6% | — | ||
| Q3 24 | 54.5% | — | ||
| Q2 24 | 55.7% | — | ||
| Q1 24 | 57.1% | — |
营业利润率AVNSAVR
| Q4 25 | 1.4% | -9343.5% | ||
| Q3 25 | 0.1% | -5190.0% | ||
| Q2 25 | -42.6% | -3379.3% | ||
| Q1 25 | 6.1% | -3917.3% | ||
| Q4 24 | -233.0% | — | ||
| Q3 24 | 7.0% | — | ||
| Q2 24 | 3.7% | — | ||
| Q1 24 | 2.4% | — |
净利率AVNSAVR
| Q4 25 | -0.7% | -9420.0% | ||
| Q3 25 | -0.8% | -5185.1% | ||
| Q2 25 | -43.9% | -3371.2% | ||
| Q1 25 | 3.9% | -3932.4% | ||
| Q4 24 | -221.2% | — | ||
| Q3 24 | 2.5% | — | ||
| Q2 24 | 1.0% | — | ||
| Q1 24 | -0.5% | — |
每股收益（稀释后）AVNSAVR
| Q4 25 | $-0.02 | $-0.74 | ||
| Q3 25 | $-0.03 | $-0.62 | ||
| Q2 25 | $-1.66 | $-0.58 | ||
| Q1 25 | $0.14 | $-0.61 | ||
| Q4 24 | $-8.64 | — | ||
| Q3 24 | $0.09 | — | ||
| Q2 24 | $0.04 | — | ||
| Q1 24 | $-0.02 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $89.8M | — |
| 总债务越低越好 | $90.3M | $22.0K |
| 股东权益账面价值 | $778.2M | $-93.0K |
| 总资产 | $1.1B | $23.0M |
| 负债/权益比越低杠杆越低 | 0.12× | — |
8季度趋势，按日历期对齐
现金及短期投资AVNSAVR
| Q4 25 | $89.8M | — | ||
| Q3 25 | $70.5M | — | ||
| Q2 25 | $90.3M | — | ||
| Q1 25 | $97.0M | $49.0M | ||
| Q4 24 | $107.7M | — | ||
| Q3 24 | $89.0M | — | ||
| Q2 24 | $92.2M | — | ||
| Q1 24 | $75.8M | — |
总债务AVNSAVR
| Q4 25 | $90.3M | $22.0K | ||
| Q3 25 | $93.4M | $26.0K | ||
| Q2 25 | $95.7M | $30.0K | ||
| Q1 25 | $98.0M | $30.0K | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
股东权益AVNSAVR
| Q4 25 | $778.2M | $-93.0K | ||
| Q3 25 | $778.0M | $3.7M | ||
| Q2 25 | $776.3M | $24.4M | ||
| Q1 25 | $839.4M | $43.3M | ||
| Q4 24 | $828.5M | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.2B | — | ||
| Q1 24 | $1.2B | — |
总资产AVNSAVR
| Q4 25 | $1.1B | $23.0M | ||
| Q3 25 | $1.1B | $19.1M | ||
| Q2 25 | $1.0B | $39.9M | ||
| Q1 25 | $1.1B | $58.8M | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $1.7B | — | ||
| Q2 24 | $1.7B | — | ||
| Q1 24 | $1.7B | — |
负债/权益比AVNSAVR
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | 0.01× | ||
| Q2 25 | 0.12× | 0.00× | ||
| Q1 25 | 0.12× | 0.00× | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.2M | $-18.5M |
| 自由现金流经营现金流 - 资本支出 | $21.3M | $-18.9M |
| 自由现金流率自由现金流/营收 | 11.8% | -6104.5% |
| 资本支出强度资本支出/营收 | 3.8% | 128.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $43.1M | $-79.8M |
8季度趋势，按日历期对齐
经营现金流AVNSAVR
| Q4 25 | $28.2M | $-18.5M | ||
| Q3 25 | $14.0M | $-18.3M | ||
| Q2 25 | $6.8M | $-19.5M | ||
| Q1 25 | $25.7M | $-21.5M | ||
| Q4 24 | $57.9M | — | ||
| Q3 24 | $23.0M | — | ||
| Q2 24 | $27.8M | — | ||
| Q1 24 | $-8.0M | — |
自由现金流AVNSAVR
| Q4 25 | $21.3M | $-18.9M | ||
| Q3 25 | $7.0M | $-19.0M | ||
| Q2 25 | $-4.2M | $-20.1M | ||
| Q1 25 | $19.0M | $-21.7M | ||
| Q4 24 | $53.1M | — | ||
| Q3 24 | $20.0M | — | ||
| Q2 24 | $21.9M | — | ||
| Q1 24 | $-12.1M | — |
自由现金流率AVNSAVR
| Q4 25 | 11.8% | -6104.5% | ||
| Q3 25 | 3.9% | -4434.5% | ||
| Q2 25 | -2.4% | -3247.9% | ||
| Q1 25 | 11.3% | -3909.5% | ||
| Q4 24 | 29.6% | — | ||
| Q3 24 | 11.7% | — | ||
| Q2 24 | 12.8% | — | ||
| Q1 24 | -7.3% | — |
资本支出强度AVNSAVR
| Q4 25 | 3.8% | 128.1% | ||
| Q3 25 | 3.9% | 180.0% | ||
| Q2 25 | 6.3% | 86.9% | ||
| Q1 25 | 4.0% | 44.6% | ||
| Q4 24 | 2.7% | — | ||
| Q3 24 | 1.8% | — | ||
| Q2 24 | 3.4% | — | ||
| Q1 24 | 2.5% | — |
现金转化率AVNSAVR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | — | ||
| Q2 24 | 15.44× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
AVR
暂无分部数据
